Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
48,446,966

-0.41 (-1.43%)

Updated Aug 16, 2024 04:01 PM ET

After-Market: $28.27 -0.03 (-0.11%) 5:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

    Healthcare ETFs Head to Head: XLV vs. VHT

    Head to head comparison of two Healthcare ETFs, XLV and VHT.

      Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

      Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.

        Conatus Entrusts Keith W. Marshall With Key Management Roles

        Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

          What to Expect from Big Pharmas After J&J's Solid Q3 Results?

          Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

            Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

            At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

              Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

              Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

                Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

                  J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

                  J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

                    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                      Arpita Dutt headshot

                      Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

                      Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.

                        J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

                        Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.

                          Arpita Dutt headshot

                          Pharma Industry Outlook - October 2017

                          New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.

                            Sanghamitra Saha headshot

                            Spin-Off ETF: Can the Outperformance Continue?

                            Spin-off activities picked up pace in the United States.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

                              Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

                                Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib

                                Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.

                                  Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study

                                  Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.

                                    Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit

                                    Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.

                                      Stock Market News For Oct 11, 2017

                                      The Dow notched up another record close on Tuesday, following a surge in shares of Wal-Mart.

                                        Arpita Dutt headshot

                                        5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

                                        Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.

                                          AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

                                          AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

                                            Arpita Dutt headshot

                                            Forget Teva (TEVA), Buy These 5 Drug Stocks Instead

                                            With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.

                                              4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

                                              The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

                                                Allergan's Botox Gets FDA Nod for Forehead Line Treatment

                                                Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.

                                                  The Zacks Analyst Blog Highlights: Pfizer, AT&T, BlackRock U.S. Bancorp and Walt Disney

                                                  The Zacks Analyst Blog Highlights: Pfizer, AT&T, BlackRock U.S. Bancorp and Walt Disney